Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

CYTK
Cytokinetics Inc.
stock NASDAQ

At Close
Jul 16, 2026 3:59:57 PM EDT
80.36USD-2.741%(-2.26)1,406,544
69.65Bid   91.99Ask   22.34Spread
Pre-market
Jul 16, 2026 9:27:30 AM EDT
81.99USD-0.763%(-0.63)322
After-hours
Jul 16, 2026 4:02:30 PM EDT
80.36USD+0.006%(0.00)38,201
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 24, 2022
07:30AM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its fourth annual Communications Fellowship Grant program, intended to support increased capacity in communications, awareness building and community engagement for nonprofit organizations serving the patient community.   GlobeNewswire Inc
Jan 10, 2022
05:00PM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2021 it granted stock options to purchase an aggregate of 90,000 shares of common stock to 9 new employees, whose employment commenced in December 2021, as a material inducement to their employment.   GlobeNewswire Inc
Jan 7, 2022
01:03PM EST  Cytokinetics, Royalty Pharma Report Funding Deals For Total Of Up To $450M   Benzinga
08:07AM EST  -- Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten -- Royalty Pharma Purchases Royalties on Future Sales of Aficamten -- Cytokinetics to Host Conference Call and Webcast Today at 8:30 a.m. ET   GlobeNewswire Inc
07:36AM EST  Cytokinetics Secures Long-term Capital From Royalty Pharma To Support Potential Commercialization Of Omecamtiv Mecarbil   RTTNews
07:30AM EST  Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten   GlobeNewswire Inc
Jan 3, 2022
04:35PM EST  Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences, Sotera Health, Eagle Pharma   Benzinga
04:12PM EST  Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights, Sema4, Repare Therapeutics, Terns Pharma, CONMED, Talkspace, Kodiak Sciences   Benzinga
04:03PM EST  Companies To Participate In JP Morgan Healthcare Conference Jan. 11: Cytokinetics, iTeos, Ultragenyx, Cara Therapeutics, Kiniksa Pharma, Nurix Therapeutics, Neurocrine Biosciences, Berkeley Lights   Benzinga
04:00PM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 pm ET.   GlobeNewswire Inc
Dec 22, 2021
10:07AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021   Benzinga
04:55AM EST  Oppenheimer Initiates Coverage On Cytokinetics with Outperform Rating, Announces Price Target of $55   Benzinga
Dec 21, 2021
04:44AM EST  HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $69   Benzinga
Dec 20, 2021
11:47AM EST  Cytokinetics Shares See Volume; Hearing HC Wainright Raises Price Target To $69   Benzinga
07:50AM EST  Cytokinetics Says JI XING To Develop Novel Cardiac Myosin Activator In Patients With Heart Failure   RTTNews
07:36AM EST  Cytokinetics And JI XING Announce Expansion Of Collaboration To Include Licensing Of Omecamtiv Mecarbil In China; Cytokinetics To Receive $70M In Committed Capital Plus Up To An Additional $330M In Potential Milestone Payments Plus Royalties   Benzinga
07:30AM EST  JI XING to Develop and CommercializeNovel Cardiac Myosin Activator in Patients with Heart Failure   GlobeNewswire Inc
Dec 17, 2021
02:08PM EST  CynergisTek Reports 'A Top 10 Public University Managed Service Client Expands Relationship With Additional Cybersecurity Services'   Benzinga
Dec 10, 2021
01:22PM EST  What 5 Analyst Ratings Have To Say About Cytokinetics   Benzinga
12:41PM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021   Benzinga
07:38AM EST  Cytokinetics Highlights Data For Its Amyotrophic Lateral Sclerosis Program Presented At Int'l. Symposium On ALS/Motor Neurone Disease   Benzinga
07:30AM EST  Cytokinetics Announces Data From Its ALS Program Presented at the   GlobeNewswire Inc
05:28AM EST  JP Morgan Initiates Coverage On Cytokinetics with Overweight Rating, Announces Price Target of $58   Benzinga
Dec 9, 2021
09:46PM EST  Cytokinetics Announces Receipt Of Breakthrough Therapy Designation From FDA for Aficamten   Benzinga
07:30AM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is a next-generation cardiac myosin inhibitor in development for the potential treatment of HCM.   GlobeNewswire Inc
Dec 7, 2021
08:26AM EST  The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Dar   Benzinga
Dec 6, 2021
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Dec 1, 2021
04:00PM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2021 it granted stock options to purchase an aggregate of 143,500 shares of common stock to 9 new employees, whose employment commenced in November 2021, as a material inducement to their employment.   GlobeNewswire Inc
08:50AM EST  Mizuho Maintains Buy on Cytokinetics, Raises Price Target to $54   Benzinga
Nov 30, 2021
04:00PM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one oral presentation and three poster presentations at the 32nd International Symposium on ALS/MND taking place online from December 7 December 10, 2021.   GlobeNewswire Inc
Nov 15, 2021
04:00PM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 30, 2021 to December 2, 2021.   GlobeNewswire Inc
07:30AM EST  Analysis from GALACTIC-HF Shows Treatment with Omecamtiv MecarbilAssociated with Significant Reduction in the Risk of Stroke   GlobeNewswire Inc
Nov 8, 2021
04:00PM EST  Cytokinetics Announces Two Presentations at the AHA Scientific   GlobeNewswire Inc
Nov 4, 2021
06:27AM EDT  HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $62   Benzinga
Nov 3, 2021
04:01PM EDT  Cytokinetics Q3 EPS $(0.95) Misses $(0.76) Estimate, Sales $5.40M Miss $6.42M Estimate   Benzinga
04:00PM EDT  Submission of NDA for Omecamtiv Mecarbil on Track to Occur in Q4 2021   GlobeNewswire Inc
09:10AM EDT  Earnings Scheduled For November 3, 2021   Benzinga
Nov 1, 2021
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 29, 2021 it granted stock options to purchase an aggregate of 68,550 shares of common stock to 8 new employees, whose employment commenced in October 2021, as a material inducement to their employment.   GlobeNewswire Inc
Oct 29, 2021
07:37AM EDT  Cytokinetics Announces Preclinical Data Relating To CK-3828136 Presented At 2021 Medicinal Chemistry Gordon Research Conference   Benzinga
07:30AM EDT  Cytokinetics Announces Preclinical Data Relating to CK-3828136   GlobeNewswire Inc
Oct 21, 2021
04:01PM EDT  Cytokinetics Announces Preclinical Data For CK-3828136 To Be Presented At 2021 Medicinal Chemistry Gordon Research Conference   Benzinga
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to the discovery and optimization of CK-3828136 (CK-136) will be presented at the 2021 Medicinal Chemistry Gordon Research Conference, taking place in West Dover, VT from October 24, 2021 to October 29, 2021.   GlobeNewswire Inc
Oct 20, 2021
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the companys outlook for the future.   GlobeNewswire Inc
Oct 8, 2021
12:11PM EDT  Where Cytokinetics Stands With Analysts   Benzinga
07:58AM EDT  Morgan Stanley Maintains Overweight on Cytokinetics, Raises Price Target to $45   Benzinga
Oct 7, 2021
12:19PM EDT  Expert Ratings For Cytokinetics   Benzinga
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021   Benzinga
07:33AM EDT  Cytokinetics Outlines Go-To-Market Strategy For Omecamtiv Mecarbil And Provides Updates On Cardiovascular Pipeline At Today's Analyst & Investor Day   Benzinga
07:30AM EDT  Go-To-Market Strategy Focuses on Educating Healthcare Professionals, Ensuring Managed Care Access, and Enacting Programs for Patient Access, Education and Support   GlobeNewswire Inc
05:07AM EDT  Jefferies Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $75   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Oct 1, 2021
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2021 it granted stock options to purchase an aggregate of 206,300 shares of common stock to 14 new employees, whose employment commenced in September 2021, as a material inducement to their employment.   GlobeNewswire Inc
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 29, 2021
06:58AM EDT  Cramer Weighs In On Cytokinetics, LegalZoom And Matterport   Benzinga
Sep 28, 2021
08:18AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments   Benzinga
07:30AM EDT  Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases   GlobeNewswire Inc
Sep 23, 2021
04:02PM EDT  Cytokinetics To Host Analyst & Investor Day Oct. 7   Benzinga
04:00PM EDT  Cytokinetics to Host Analyst & Investor Day on October 7, 2021   GlobeNewswire Inc
03:31PM EDT  Cytokinetics Wins $571.5K Department Of Health And Human Services Contract For 'Purchase of one (1) Brand Name or Equal Cytek Aurora Five (5) Laser Spectral Cell Sorter'   Benzinga
03:30PM EDT  Cytokinetics Wins $571.5K Health And Human Services Contract For 'Purchase of one (1) Brand Name or Equal Cytek Aurora Five (5) Laser Spectral Cell Sorter'   Benzinga
Sep 17, 2021
07:36AM EDT  The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold   Benzinga
Sep 12, 2021
11:45AM EDT  Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with AficamtenSupporting Progression to Phase 3 Clinical Trial   GlobeNewswire Inc
Sep 8, 2021
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences in September:   GlobeNewswire Inc
Sep 7, 2021
07:30AM EDT  Cytokinetics to Host Investor Call and Webcast to Discuss the Full   GlobeNewswire Inc
Sep 1, 2021
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 31, 2021 it granted stock options to purchase an aggregate of 113,600 shares of common stock to 10 new employees, whose employment commenced in August 2021, as a material inducement to their employment.   GlobeNewswire Inc
Aug 31, 2021
08:15AM EDT  The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical   Benzinga
07:40AM EDT  Cytokinetics To Present Results From REDWOOD-HCM And GALACTIC-HF to Be Presented At HFSA Annual Scientific Meeting   Benzinga
07:30AM EDT  Full Results from REDWOOD-HCM Expand on Positive Topline Results of Aficamtenin Patients with Obstructive Hypertrophic Cardiomyopathy   GlobeNewswire Inc
Aug 19, 2021
07:30AM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) and Cure SMA today announced the renewal of their partnership to increase education, awareness, public policy and fundraising for spinal muscular atrophy (SMA). Cytokinetics will be a National Gold Sponsor in support of several key Cure SMA initiatives across the United States.   GlobeNewswire Inc
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 6, 2021
06:09AM EDT  HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $58   Benzinga
Aug 5, 2021
05:26PM EDT  Cytokinetics: Q2 Earnings Insights   Benzinga
04:15PM EDT  Cytokinetics Sees FY21 Sales $23M-$28M Vs. $28.07M Est.   Benzinga
04:14PM EDT  Cytokinetics Q2 EPS $(0.86) Misses $(0.65) Estimate, Sales $2.84M Down From $3.59M YoY   Benzinga
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 2, 2021
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 30, 2021 it granted stock options to purchase an aggregate of 258,750 shares of common stock to 15 new employees, whose employment commenced in July 2021, as a material inducement to their employment.   GlobeNewswire Inc
07:30AM EDT  Cytokinetics Announces Start Of COURAGE-ALS Phase 3 Clinical Trial Of Reldesemtiv In Patients With Amyotrophic Lateral Sclerosis   Benzinga
07:30AM EDT  Pivotal Trial Builds on Results from FORTITUDE-ALS which Demonstrated Slowing of Declineof SVC and ALSFRS-R in Patients on Reldesemtiv Compared to Placebo   GlobeNewswire Inc
Jul 23, 2021
03:00PM EDT  Cell Analysis Instruments Provider Cytek Biosciences Kick Starts Trading After Pricing IPO At $17   Benzinga
12:45PM EDT  Cytokinetics Announces Closing of Public Offering of Common Stock   GlobeNewswire Inc
Jul 22, 2021
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 5, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the companys outlook for the future.   GlobeNewswire Inc
Jul 21, 2021
08:16AM EDT  Cytokinetics Late Yesterday Priced Its 10M Share Offering At $27.50/Share   Benzinga
Jul 20, 2021
11:15PM EDT  Cytokinetics Announces Pricing of Public Offering of Common Stock   GlobeNewswire Inc
02:21PM EDT  Why Cytokinetics (CYTK) Shares Are Trading Higher Today?   Benzinga
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
07:48AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
06:18AM EDT  Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $40   Benzinga
Jul 19, 2021
04:00PM EDT  Cytokinetics Announces Proposed $200M Public Offering of Common Stock   Benzinga
04:00PM EDT  Cytokinetics Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
02:34PM EDT  Mid-Afternoon Market Update: Dow Tumbles 850 Points; Aehr Test Systems Shares Surge   Benzinga
02:32PM EDT  Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data   Benzinga
12:33PM EDT  HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $53   Benzinga
12:10PM EDT  Cytokinetics Shares Quiet Here, Up 45% For Session; Traders Circulate HC Wainwright Note Showing Raised Price Target To $53   Benzinga
12:09PM EDT  Mid-Day Market Update: Crude Oil Dips 6%; Cytokinetics Shares Spike Higher   Benzinga
11:35AM EDT  Needham Maintains Buy on Cytokinetics, Raises Price Target to $48   Benzinga
11:29AM EDT  Watching Cytokinetics Shares; Hearing Needham Raises Price Target To Street High From $33 To $48   Benzinga
11:28AM EDT  Watching Cytokinetics Shares; Hearing Needham Raises Price Target To Street High Of $48   Benzinga
10:21AM EDT  Mid-Morning Market Update: Markets Open Lower; AutoNation Profit Beats Estimates   Benzinga
09:56AM EDT  Cytokinetics, Inc. (CYTK) shares are spiking on Monday morning trade after the company reported positive results from the phase 2 trial of CK-274, a cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy or HCM.   RTTNews
08:12AM EDT  Cytokinetics Shares Gain On Positive Data From Heart Disease Candidate   Benzinga
07:37AM EDT  Cytokinetics Announces Announces Phase 2 Clinical Trial Of CK-274 'Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in Patients with Obstructive Hypertrophic Cardiomyopathy'   Benzinga
07:36AM EDT  Phase 2 Clinical Trial of CK-274 Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in Patients with Obstructive Hypertrophic Cardiomyopathy   GlobeNewswire Inc
Jul 1, 2021
04:00PM EDT  Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Jun 30, 2021
12:23PM EDT  Cytokinetics Publishes Study Titled 'A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) (COURAGE-ALS)' To ClinicalTrials.Gov Website   Benzinga
07:31AM EDT  Cytokinetics Highlights Presentation Of Additional Results From GALACTIC-HF At European Society of Cardiology Heart Failure 2021   Benzinga
07:30AM EDT  Cytokinetics Announces Additional Results From GALACTIC-HF   GlobeNewswire Inc
Jun 23, 2021
07:31AM EDT  Cytokinetics Announces Three Presentations To Occur At European Society Of Cardiology Heart Failure 2021 Congress Jun. 29   Benzinga
07:30AM EDT  Cytokinetics Announces Three Presentations to Occur at the   GlobeNewswire Inc
Jun 15, 2021
07:37AM EDT  Cytokinetics Announces Completion Of Patient Enrollment In METEORIC-HF   RTTNews
07:32AM EDT  Cytokinetics Announces Completion Of Enrollment In METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure With Reduced Ejection Fraction   Benzinga
07:30AM EDT  Cytokinetics Announces Completion of Enrollment in METEORIC-HF,   GlobeNewswire Inc
Jun 2, 2021
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in three virtual fireside chats at the following investor conferences:   GlobeNewswire Inc
Jun 1, 2021
04:00PM EDT  Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
May 19, 2021
07:40AM EDT  Cytokinetics, ALS Association Renew Partnership To Fight Against Amyotrophic Lateral Sclerosis   RTTNews
07:33AM EDT  Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS   Benzinga
07:30AM EDT  Cytokinetics and The ALS Association Renew Partnership to Advance   GlobeNewswire Inc
May 17, 2021
01:02PM EDT  Cytokinetics Post-Hoc Data Suggests Omecamtiv Mecarbil Works Better In High-Risk Patients For Heart Failure   Benzinga
08:26AM EDT  Cytokinetics Presents Data From Secondary Analysis Of GALACTIC-HF   RTTNews
08:01AM EDT  Cytokinetics Highlights Presentaiton Of Secondary Analysis Of GALACTIC-HF At American College Of Cardiology 70th Annual Scientific SessionAnd Publication In Journal Of American College Of Cardiology   Benzinga
08:00AM EDT  Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented   GlobeNewswire Inc
May 16, 2021
08:00AM EDT  Cytokinetics Announces Presentations Related to Health Economics   GlobeNewswire Inc
May 10, 2021
04:00PM EDT  Cytokinetics Announces Three Upcoming Presentations Related to   GlobeNewswire Inc
May 6, 2021
04:01PM EDT  Cytokinetics Q1 EPS $(0.66) Misses $(0.58) Estimate, Sales $6.55M Miss $6.58M Estimate   Benzinga
04:00PM EDT  Secondary Analysis from GALACTIC-HFto be Presented in Late Breaking Clinical Trial Session at ACC.21   GlobeNewswire Inc
08:42AM EDT  Cytokinetics Announces Start Of Open-Label Extension Study For Patients Completing REDWOOD-HCM   Benzinga
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
07:30AM EDT  Cytokinetics Announces Start of Open-Label Extension Study for   GlobeNewswire Inc
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
May 5, 2021
04:00PM EDT  Cytokinetics to Hold Annual Meeting of Stockholders   GlobeNewswire Inc
May 4, 2021
07:38AM EDT  Cytokinetics Says Cohort 3 Of REDWOOD-HCM Is Open To Enrollment   Benzinga
07:30AM EDT  Cytokinetics Announces Cohort 3 of REDWOOD-HCM is Open to Enrollment   GlobeNewswire Inc
May 3, 2021
04:00PM EDT  Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
02:48PM EDT  Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics   Benzinga
Apr 22, 2021
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the companys outlook for the future.   GlobeNewswire Inc
Apr 19, 2021
10:25AM EDT  Morgan Stanley Maintains Overweight on Cytokinetics, Raises Price Target to $35   Benzinga
Apr 12, 2021
07:40AM EDT  Cytokinetics Highlights Presentation Of Preclinical Data For CK-3773274 AtAmerican Chemical Society Spring 2021 Virtual Meeting   Benzinga
07:38AM EDT  Cytokinetics Presents Preclinical Data For CK-3773274 At American Chemical Society Spring 2021 Virtual Meeting   RTTNews
07:30AM EDT  Cytokinetics Announces Preclinical Data for CK-3773274 Presented   GlobeNewswire Inc
Apr 5, 2021
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 3:00 PM ET.   GlobeNewswire Inc
Apr 2, 2021
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to CK-3773274 (CK-274), including data regarding its discovery and key optimization parameters, will be presented at the American Chemical Society Spring 2021 Virtual Meeting, taking place online from April 5, 2021 to April 30, 2021.   GlobeNewswire Inc
Apr 1, 2021
04:00PM EDT  Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Mar 18, 2021
07:31AM EDT  Cytokinetics Highlights Recent Presentation Of Secondary Analysis From GALACTIC-HF To Be Presented In Late Breaking Clinical Trial Session At American College Of Cardiology 70th Annual Scientific Session & Expo   Benzinga
07:30AM EDT  Cytokinetics Announces Secondary Analysis From GALACTIC-HF to Be   GlobeNewswire Inc
Mar 12, 2021
09:01AM EST  Wolfe Research Initiates Coverage On Cytokinetics with Outperform Rating, Announces Price Target of $50   Benzinga
Mar 2, 2021
04:00PM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021 and participate in a fireside chat at the virtual Barclays Global Healthcare Conference on March 11, 2021 at 9:45 AM ET.   GlobeNewswire Inc
Feb 26, 2021
04:33PM EST  Cytokinetics Announces Inducement Grants Under Nasdaq Listing   GlobeNewswire Inc
07:30AM EST  Cytokinetics Joins Global Initiative to Recognize International   GlobeNewswire Inc
Feb 25, 2021
04:01PM EST  Cytokinetics Q4 EPS $(0.62) Down From $(0.52) YoY, Sales $6.72M Miss $8.56M Estimate   Benzinga
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 18, 2021
07:44AM EST  Cytokinetics Names Muna Bhanji To Board   RTTNews
07:30AM EST  Cytokinetics Names Muna Bhanji to Board of Directors   GlobeNewswire Inc
Feb 11, 2021
04:00PM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 25, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the companys outlook for the future.   GlobeNewswire Inc
Feb 2, 2021
07:30AM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its third annual Communications Fellowship Grant program, intended to support increased capacity in communications, awareness building and community engagement for nonprofit organizations.   GlobeNewswire Inc
Feb 1, 2021
04:00PM EST  Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Jan 20, 2021
06:33AM EST  HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $41   Benzinga
Jan 13, 2021
07:34AM EST  Cytokinetics Says First Patient Dosed In Cohort 2 Of REDWOOD-HCM; Earns $2.5 Mln Milestone   RTTNews
07:33AM EST  Cytokinetics Reports First Patient Dosed In Cohort 2 Of Redwood-HCM   Benzinga
07:30AM EST  Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM   GlobeNewswire Inc
Jan 11, 2021
07:55AM EST  Cytokinetics, Incorporated (CYTK) announced the FDA has granted orphan drug designation to CK-3773274 (CK-274) for the treatment of symptomatic hypertrophic cardiomyopathy. The company anticipates results from REDWOOD-HCM, ongoing phase 2 clinical trial, in mid-year.   RTTNews
07:47AM EST  Cytokinetics Says FDA Has Granted Orphan Drug Designation To CK-3773274   RTTNews
07:35AM EST  Cytokinetics Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy   Benzinga
07:30AM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CK-3773274 (CK-274) for the treatment of symptomatic hypertrophic cardiomyopathy (HCM). CK-274 is a next-generation cardiac myosin inhibitor in development for the potential treatment of HCM.   GlobeNewswire Inc
Jan 6, 2021
04:00PM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021.   GlobeNewswire Inc
Dec 23, 2020
07:36AM EST  Cytokinetics Regains European Rights To Omecamtiv Mecarbil   RTTNews
07:31AM EST  Cytokinetics Reports Regained European Rights To Omecamtiv Mecarbil   Benzinga
07:30AM EST  Cytokinetics Regains European Rights to Omecamtiv Mecarbil   GlobeNewswire Inc
Dec 16, 2020
12:29PM EST  Morgan Stanley Maintains Overweight on Cytokinetics, Raises Price Target to $24   Benzinga
Dec 14, 2020
07:34AM EST  Cytokinetics Reports Added Data Related To Impact Of Patient Characteristics On Treatment Effect In FORTITUDE-ALS Phase 2 Trial   Benzinga
07:30AM EST  Cytokinetics Announces Data and Trial Design Presented at the   GlobeNewswire Inc
Dec 9, 2020
07:31AM EST  Cytokinetics Announces Progression Of REDWOOD-HCM To Cohort 2   Benzinga
Dec 7, 2020
07:37AM EST  Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the 17th Global Cardiovascular Clinical Trialists   Benzinga
07:30AM EST  Supplemental Analyses of Primary Composite Endpoint Further Demonstrate Effect of Omecamtiv Mecarbil In Patients with Lower Ejection Fraction   GlobeNewswire Inc
Dec 3, 2020
07:30AM EST  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS/MND taking place online from December 9 December 11, 2020.   GlobeNewswire Inc
Dec 1, 2020
04:00PM EST  Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
07:44AM EST  Cytokinetics To Present Results From GALACTIC-HF At Global Cardiovascular Clinical Trialists Forum   RTTNews
07:38AM EST  Cytokinetics Announces Additional Results From GALACTIC-HF to be Presented at the 17th Global Cardiovascular Clinical Trialists Forum   Benzinga
07:30AM EST  Cytokinetics Announces Additional Results From GALACTIC-HF to be   GlobeNewswire Inc
Nov 24, 2020
04:00PM EST  Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in virtual fireside chats at the Piper Sandler 32nd Annual Healthcare Conference taking place December 1-3, 2020, and the 3rd Annual Evercore ISI HealthCONx Conference on Thursday, December 3, 2020 at 3:05 PM ET.   GlobeNewswire Inc
Nov 23, 2020
08:37AM EST  Cytokinetics Inc. (CYTK) said Monday that Amgen has elected to terminate the Collaboration and Option Agreement, dated December 20, 2006 between the companies and end its collaboration with Cytokinetics, effective May 20, 2021. Amgen plans to transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to Cytokinetics.   RTTNews
07:36AM EST  Amgen Provides Notice To Cytokinetics Of Termination Of Its Collaboration For Omecamtiv Mecarbil And AMG 594   RTTNews
07:33AM EST  Amgen Says Has Provided Notice To Cytokinetics Of Termination Of Its Collaboration And Its Intention To Transition The Development And Commercialization Rights For Omecamtiv Mecarbil And AMG 594   Benzinga
07:33AM EST  Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen   Benzinga
07:30AM EST  Company Committed to Advancing OmecamtivMecarbil with Initial Focus on Preparationsfor Regulatory Interactions Following Positive Results of GALACTIC-HF   GlobeNewswire Inc
Nov 20, 2020
07:30AM EST  Cytokinetics Names Nancy Wysenski to Board of Directors   GlobeNewswire Inc
Nov 16, 2020
08:12AM EST  Morgan Stanley Maintains Overweight on Cytokinetics, Lowers Price Target to $22   Benzinga
07:40AM EST  Cytokinetics Reports Preclinical Data For CK-274, CK-271 Shared In Poster Presentations At American Heart Association Scientific Sessions   Benzinga
07:30AM EST  Cytokinetics Announces Presentations Related to Health Economics   GlobeNewswire Inc
07:30AM EST  Cytokinetics Announces Preclinical Data for CK-3773274 and   GlobeNewswire Inc
Nov 13, 2020
11:41AM EST  Cytokinetics Announces Results From GALACTIC-HF Presented At Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions, Published In New England Journal Of Medicine   Benzinga
11:35AM EST  Trial Met Primary Composite Endpoint of Reduction in Heart Failure Events or Cardiovascular Death; Did Not Meet Secondary Endpoints Including Reduction in Cardiovascular Death   GlobeNewswire Inc
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 10, 2020
04:00PM EST  Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 6, 2020
07:31AM EST  Cytokinetics Highlights 6 Presentations Related To Heart Failure, Hypertrophic Cardiomyopathy At American Heart Association Scientific Sessions Nov. 12 2:30-3:30 p.m. EST   Benzinga
07:30AM EST  Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session   GlobeNewswire Inc
Nov 4, 2020
04:01PM EST  Cytokinetics Q3 EPS $(0.05) Beats $(0.34) Estimate, Sales $41.69M Up From $6.05M YoY   Benzinga
04:00PM EST  Topline Results From GALACTIC-HF Show Trial Met Primary Composite Endpointof Reduction in Cardiovascular Death or Heart Failure Events; Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death   GlobeNewswire Inc
08:21AM EST  The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings   Benzinga
04:41AM EST  Earnings Scheduled For November 4, 2020   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 29, 2020
09:36AM EDT  Goldman Sachs Initiates Coverage On Cytokinetics with Neutral Rating, Announces Price Target of $16   Benzinga
Oct 21, 2020
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2020 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the companys outlook for the future.   GlobeNewswire Inc
Oct 12, 2020
08:02AM EDT  Morgan Stanley Maintains Overweight on Cytokinetics, Lowers Price Target to $24   Benzinga
Oct 8, 2020
02:30PM EDT  Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Consumer Portfolio Services Shares Spike Higher   Benzinga
12:45PM EDT  Mid-Day Market Update: Eaton Vance Jumps Following Acquisition News; Cytokinetics Shares Plunge   Benzinga
12:10PM EDT  HC Wainwright & Co. Maintains Buy on Cytokinetics, Lowers Price Target to $43   Benzinga
10:14AM EDT  Return On Capital Employed Overview: Cytokinetics   Benzinga
10:11AM EDT  Mid-Morning Market Update: Markets Open Higher; Domino's Pizza Earnings Miss Estimates   Benzinga
10:02AM EDT  Cytokinetics, Inc. (CYTK) shares are sliding more than 42 percent on Thursday morning trade.   RTTNews
08:49AM EDT  Amgen: GALACTIC-HF Trial Meets Primary Composite Endpoint;   RTTNews
08:36AM EDT  Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF Trial Did Not Meet Secondary Endpoint   RTTNews
08:32AM EDT  Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure   Benzinga
08:31AM EDT  Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A   PR Newswire
08:30AM EDT  Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events   GlobeNewswire Inc
Oct 5, 2020
04:00PM EDT  Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
09:59AM EDT  Shares of Cytokinetics, Inc. (CYTK) are gaining more than 14 percent or $3.50 in Monday's morning trade at $27.49 after the biotechnology company said new results from the Phase 2 COSMIC-HF clinical trial showed that treatment with Omecamtiv Mecarbil was associated with improved right ventricular function.   RTTNews
07:35AM EDT  Cytokinetics Highlights Data From Two Presentations At HFSA Virtual Annual Scientific Meeting 2020   Benzinga
07:30AM EDT  Real-World Population Representative of Patients Enrolled in GALACTIC-HFIndicate a High-Need, High-Risk Populationwith Heart Failure   GlobeNewswire Inc
Oct 2, 2020
08:01AM EDT  Cytokinetics Publishes Manuscript Detailing Baseline Characteristics Of GALACTIC-HF In European Journal   RTTNews
07:31AM EDT  Cytokinetics Highlights Publication Of Manuscript Detailing Baseline Characteristics Of GALACTIC-HF In European Journal Of Heart Failure   Benzinga
07:30AM EDT  Heart Failure Patients in Phase 3 Clinical Trial of Omecamtiv Mecarbil Are at High Risk of Cardiovascular Events and Symptom Burden   GlobeNewswire Inc
Sep 24, 2020
04:01PM EDT  Cytokinetics To Report New Data At Heart Failure Society Of America Meeting Sept. 30-Oct. 6   Benzinga
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data will be presented at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020 taking place online from September 30, 2020 October 6, 2020.   GlobeNewswire Inc
07:45AM EDT  Cytokinetics Announces Call For Proposals For Third Annual Communications Fellowship Program   RTTNews
07:30AM EDT  GrantsSupportCommunity Engagement forPatient Advocacy OrganizationsFocused on Cardiovascular andNeuromuscular Diseases   GlobeNewswire Inc
Sep 23, 2020
07:30AM EDT  Cytokinetics Announces Initiation Of Phase 1 Clinical Study Of CK-3772271   Benzinga
07:30AM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 placebo-controlled, single ascending dose clinical study of CK-3772271 (CK-271). CK-271 is a second cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM).   GlobeNewswire Inc
Sep 21, 2020
02:21PM EDT  Cytokinetics Option Alert: Nov 20 $30 Calls Sweep (2) near the Ask: 2000 @ $4.75 vs 188 OI; Earnings 10/29 After Close [est] Ref=$20.36   Benzinga
Sep 17, 2020
07:44AM EDT  Cytokinetics Announces GALACTIC-HF Accepted For Presentation At AHA Scientific Sessions   RTTNews
07:30AM EDT  Cytokinetics Announces GALACTIC-HF Accepted for Presentation In   GlobeNewswire Inc
Sep 2, 2020
04:00PM EDT  Cytokinetics to Participate in Upcoming Investor Conferences   GlobeNewswire Inc
Aug 26, 2020
07:30AM EDT  Cytokinetics and Cure SMA Renew Partnership to Advance Education   GlobeNewswire Inc
Aug 18, 2020
07:31AM EDT  Cytokinetics Announces $1M Grant And Four-Year Partnership With HCM Registry   Benzinga
07:30AM EDT  Cytokinetics Announces Partnership to Improve Prediction of Risk   GlobeNewswire Inc
Aug 6, 2020
04:02PM EDT  Cytokinetics Narrows 2020 Net Cash Guidance To $110M-$115M   Benzinga
04:01PM EDT  Cytokinetics Q2 EPS $(0.68) Misses $(0.57) Estimate, Sales $3.59M Miss $4.07M Estimate   Benzinga
07:57AM EDT  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO   Benzinga
Jul 23, 2020
04:00PM EDT  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 2020 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the companys outlook for the future.   GlobeNewswire Inc
09:22AM EDT  Piper Sandler Maintains Overweight on Cytokinetics, Raises Price Target to $36   Benzinga
06:15AM EDT  HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $59   Benzinga
Jul 21, 2020
04:00PM EDT  Cytokinetics Announces Closing of Public Offeringof   GlobeNewswire Inc
Jul 20, 2020
05:11AM EDT  80 Biggest Movers From Friday   Benzinga
Jul 17, 2020
12:00PM EDT  Mid-Day Market Update: Dow Falls 50 Points; ALX Oncology Shares Spike Higher   Benzinga
05:46AM EDT  Cytokinetics Prices 7.3M Share Public Offering of Common Stock @$24/Share   Benzinga
05:08AM EDT  64 Biggest Movers From Yesterday   Benzinga
Jul 16, 2020
11:32PM EDT  Cytokinetics Announces Pricing of Public Offering of Common Stock   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC